Clinical Pharmacists Role in the Management of Hypertension in Jordan

University of Jordan

Status: Completed

Conditions: Hypertension

Treatments: Other: pharmaceutical care services

Study type: Interventional

Funder types: Other

Identifiers

NCT01079494

JU8071383

Details and patient eligibility

About

Background: studies have demonstrated the crucial role of clinical pharmacists as integrated part of heath care team. Not only in Jordan but also in the Middle East region, clinical pharmacy practice is not well established. This current study is the first to evaluate physicians - pharmacists' collaborative approach to uncontrolled blood pressure in Jordan and the Middle East.

Full description

Objective: this study aimed to evaluate clinical pharmacists' role in the management of uncontrolled hypertensive patients in Jordan. Design: single blinded randomized controlled clinical trial. Patients: 253 patients with uncontrolled hypertension specified as higher blood pressure readings than the recommended goals by the seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC VII) at the time of enrollment.

Interventions: patients were randomly allocated to an intervention or control group: 130 and 123 patients, respectively. Patients in both arms were followed up for 6 months. In the intervention group, patients were managed by physician-clinical pharmacist team. In the control group, patients were managed by physician(s) only and were not provided pharmaceutical care services.

Enrollment: 266 patients

Sex: All

Ages: 21 to 88 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with uncontrolled BP, receiving 0-3 antihypertensive drugs with no change in the regimen or dose within the past 3 month.

Exclusion criteria

• Patients with hypertensive urgency or emergency with BP more than (180/110).
• Patients with recent stroke or myocardial infraction (within past 6 months).
• Patients with Class III or IV Chronic heart Failure (CHF).
• Patients with Unstable angina.
• Patients with Serious renal or hepatic disease.
• Pregnant patients.
• Patients with Dementia or cognitive impairment.
• If the patient is unable to provide informed written consent.

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

266 participants in 2 patient groups

intervention group

Active Comparator group

Description:

physician-pharmacist teamwork

Treatment:

Other: pharmaceutical care services

control

No Intervention group

Description:

physician only team